Summary: Researchers have identified a pivotal cellular shift that appears to determine whether Alzheimer’s pathology progresses to clinical dementia. By analyzing brain tissue from older adults—including cognitively healthy centenarians—the team mapped how microglia, the brain’s resident immune cells, change their programs in response to amyloid‑beta and tau. These cellular shifts reveal active mechanisms of resilience and point to therapeutic opportunities to prevent the transition to dementia.
The study shows that cognitive resilience is not merely the absence of amyloid‑beta plaques or tau tangles but an active, cell‑level process driven by specific microglial programs that can disconnect pathological protein buildup from neurodegeneration. These insights identify priority targets for therapies aimed at halting disease progression before a critical tipping point is reached.
Key Facts
- The pathology paradox: More than 55 million people worldwide live with Alzheimer’s disease biology, yet classic biomarkers—amyloid‑beta plaques and tau tangles—do not inevitably produce dementia. Some individuals retain normal cognition despite heavy pathology, indicating active resilience mechanisms at the cellular level.
- Six tissue domains mapped: Using spatial transcriptomics combined with single‑cell sequencing on human donor samples, the researchers defined six distinct tissue domains that reflect the spatial and temporal stages of Alzheimer’s progression.
- Microglial shift from inflammation to antigen presentation: Microglia show a clear behavioral pivot during disease progression:
- Early stage: Microglia adopt a localized inflammatory profile closely associated with amyloid‑beta plaques.
- Late stage: Microglia shift into an antigen‑presenting state that appears alongside tau pathology and active neurodegeneration.
- Two distinct routes to resilience: The data reveal age‑dependent pathways by which brains resist clinical decline:
- Octogenarian route: Individuals in their 80s who carry high plaque burdens but remain cognitively intact display the early microglial inflammatory response but block the transition into the late, degenerative immune state.
- Centenarian route: Cognitively healthy people over 100 activate the late microglial program, but in their case this state is uncoupled from tau accumulation and destructive neurodegeneration.
- Targeting the tipping point: The authors highlight microglial state transitions—pathways such as TREM2—as promising intervention points to preserve beneficial early responses and prevent inflammatory programs from triggering tau‑linked cognitive decline.
Source: VIB
Researchers from VIB, KU Leuven, the UK‑DRI and Muna Therapeutics, with funding from ERC and others, have uncovered a critical biological transition that may determine whether Alzheimer’s pathology leads to dementia.
By studying superior frontal cortex tissue from older adults with and without cognitive decline—and from cognitively intact centenarians with comparable amyloid‑beta accumulation—the team identified specific cellular programs and immune states tied to either disease progression or resilience.
Published in Nature Medicine, the work indicates that changes in microglial behavior could be central therapeutic targets for future Alzheimer’s treatments.
“This has been an exciting journey with many partners. The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia,” says Prof. Bart De Strooper (VIB‑KU Leuven Center for Neuroscience, KU Leuven), ERC grantee and co‑senior author of the study.
Alzheimer’s disease is defined by amyloid‑β plaques and tau tangles, but these hallmarks do not directly predict cognitive decline in all individuals. Growing evidence suggests that the brain’s cellular responses—particularly those of microglia—play a decisive role in whether pathology translates into neurodegeneration and dementia.
Microglia markedly change their activity during disease progression. Mapping those changes at single‑cell resolution helps explain why some people remain resistant to Alzheimer’s effects and reveals cellular targets that could be manipulated to delay or prevent clinical decline.
Comparing brains from people with dementia, those without, and cognitively healthy centenarians, the researchers identified unique microglial states associated with resilience. These states demonstrate that resilience can be achieved either by preventing harmful microglial transitions or by decoupling later microglial programs from tau‑related damage.
“Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia,” adds Prof. Mark Fiers (VIB‑KU Leuven), co‑senior author of the study.
Mapping a critical transition in Alzheimer’s disease
To explore resilience mechanisms, the team combined spatial transcriptomics and single‑nucleus RNA sequencing to profile tissue regions at cellular resolution. They defined six tissue domains that form a spatial pathological continuum of Alzheimer’s disease. A central inflection point separates domains linked primarily to amyloid‑β from those associated with tau and neuronal loss.
Crossing this inflection point coincides with a striking microglial reprogramming: early plaque‑associated inflammatory signatures give way to late antigen‑presenting phenotypes. The timing of this transition appears to be a decisive factor in whether Alzheimer’s pathology advances toward dementia.
Two different routes to resilience
Resilience emerges through distinct biological strategies. In individuals in their 80s who remain dementia‑free despite plaques, microglia mount an early inflammatory response but do not progress into the late, antigen‑presenting state linked to degeneration. In centenarians, microglia may activate the late program, yet that activation is disconnected from tau accumulation and tissue damage.
These observations imply that resilience is not a single phenomenon but rather multiple, age‑dependent cellular adaptations that change how the brain responds to pathology. Therapeutic approaches that preserve early beneficial microglial functions or prevent harmful transitions could be most effective if applied before the brain reaches the tipping point where inflammation becomes tau‑associated and drives cognitive decline.
“These findings open new opportunities to target microglial states—especially pathways such as TREM2—and extend resilience rather than simply focusing on plaque removal. We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression,” concludes Niels Plath, CSO of Muna Therapeutics.
Key Questions Answered:
A: It depends on how their microglia respond. This study shows resilient brains use specific microglial programs that either prevent the shift into harmful immune states or disconnect those states from destructive tau pathology.
A: One pathway—seen in octogenarians—retains an early inflammatory microglial reaction to plaques but blocks the later, degenerative transition. The other—seen in centenarians—engages the later microglial program but uncouples it from tau‑associated damage.
A: It shifts strategy from solely removing protein aggregates toward managing cell states. Drugs that preserve beneficial microglial functions or prevent transitions at the amyloid‑beta/tau interface—targeting molecules like TREM2—could extend resilience and prevent progression to dementia.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by our staff.
About this Alzheimer’s disease research news
Author: Gunnar De Winter
Source: VIB
Contact: Gunnar De Winter – VIB
Image: The image is credited to Neuroscience News
Original Research: Open access. “Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience” by Ashley Lu et al., published in Nature Medicine. DOI: 10.1038/s41591-026-04393-8
Abstract
Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
Alzheimer’s disease is not an unavoidable consequence of amyloid‑beta and tau accumulation but a dynamic process shaped by how brain cells respond to these proteins. To untangle these responses, the authors combined spatial transcriptomics and single‑nucleus RNA sequencing of the superior frontal cortex from octogenarians with and without dementia and from cognitively intact centenarians with comparable amyloid‑beta loads.
They identified six tissue domains forming a spatial continuum of pathology, with a key inflection point marked by a switch from amyloid‑associated inflammatory changes to tau‑related cellular programs. This switch coincided with a microglial transition from early inflammatory profiles to late antigen‑presenting phenotypes—described as early and late plaque‑induced gene (PIG) programs.
Resilient individuals followed different patterns: octogenarians without dementia lacked late PIG activation, while centenarians showed late PIG activation that did not associate with tau accumulation. These divergent mechanisms position microglial state transitions at the amyloid‑beta/tau interface as candidate resilience points with potential therapeutic relevance.